Literature DB >> 14641818

Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells.

Jae-Won Soh1, Yun-Sil Lee, I Bernard Weinstein.   

Abstract

Protein kinase C (PKC) is a multigene family consisting of at least 11 isoforms that play key roles in growth control and tumorigenesis. To understand the roles of specific isoforms of PKC in breast cancer, we generated derivatives of the human breast cancer cell line MCF-7 that stably overexpress dominant negative mutants (REG) of PKC-alpha, -epsilon, or -zeta, which encode only the regulatory domains of the respective isoforms. When stimulated to re-enter the cell cycle after serum starvation, the MCF-7/PKC-alpha-REG cell line exhibited enhanced cell-cycle progression in comparison to the control cell line. These cells also showed increased sensitivity to growth inhibition and induction of apoptosis in response to various cytotoxic stimuli, including serum starvation, tamoxifen, and gamma-radiation. Western blot analysis indicated that the MCF-7/PKC-alpha-REG cell line displayed marked decreases in the levels of the cyclin-dependent kinase inhibitor p21CIP1 and the anti-apoptotic protein bcl-2. Similar, but less striking, effects were seen in the MCF-7/PKC-epsilon-REG cell line, and the MCF-7/PKC-zeta-REG cell line showed minimal changes, when compared to the control cells. Taken together, these results suggest that the endogenous PKC-alpha in MCF-7 cells plays a critical role in regulating cell-cycle control and apoptosis, in part through upregulating the expression of p21CIP1 and bcl-2. Therefore, inhibitors of PKC-alpha may potentiate the activity of cytotoxic agents in the therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14641818     DOI: 10.1046/j.1359-4117.2003.01087.x

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  8 in total

Review 1.  Classical Protein Kinase C: a novel kinase target in breast cancer.

Authors:  R K Singh; S Kumar; M S Tomar; P K Verma; S P Singh; P K Gautam; A Acharya
Journal:  Clin Transl Oncol       Date:  2018-07-30       Impact factor: 3.405

2.  Protein kinase Cα suppresses the expression of STC1 in MDA-MB-231 breast cancer cells.

Authors:  Louise Cornmark; Gry Kalstad Lønne; Annika Jögi; Christer Larsson
Journal:  Tumour Biol       Date:  2011-07-01

3.  Genetic inhibition of protein kinase Cε attenuates necrosis in experimental pancreatitis.

Authors:  Yannan Liu; Jingzhen Yuan; Tanya Tan; Wenzhuo Jia; Aurelia Lugea; Olga Mareninova; Richard T Waldron; Stephen J Pandol
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-17       Impact factor: 4.052

Review 4.  Protein kinase Cepsilon makes the life and death decision.

Authors:  Alakananda Basu; Usha Sivaprasad
Journal:  Cell Signal       Date:  2007-05-01       Impact factor: 4.315

5.  Protein kinase Calpha-induced derepression of the human luteinizing hormone receptor gene transcription through ERK-mediated release of HDAC1/Sin3A repressor complex from Sp1 sites.

Authors:  Mingjuan Liao; Ying Zhang; Maria L Dufau
Journal:  Mol Endocrinol       Date:  2008-03-27

6.  PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis.

Authors:  Piotr Jasinski; Pawel Zwolak; Kaoru Terai; Daniel Borja-Cacho; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2009-10-01       Impact factor: 3.850

7.  Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells.

Authors:  Seong-Ho Lee; Maria Cekanova; Seung Joon Baek
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

8.  A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.

Authors:  Pit Foong Chan; Kok Pian Ang; Roslida Abd Hamid
Journal:  Biometals       Date:  2021-02-08       Impact factor: 2.949

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.